🔗 Share this article

Given that the US proceeds with sweeping changes to its vaccine guidelines, a particular individual has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus shots throughout the pandemic and has focused upon potential fatalities after Covid immunization in her recent position at the FDA.

Planned Overhauls to Childhood Immunization Schedule

Health officials planned to unveil radical revisions to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would put the US out of alignment with many the international standard with little proof for public health gain. The announcement has been postponed until the new year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US so as to align more in line with Denmark, a society with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

To date public appearances, she has kept her attention on immunizations – usually the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has little discernible track record in medication creation, regulation or leadership, which has been standard for former leaders of the CBER. She has served at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the CDER, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in running a sizeable institution. She has no expertise in drug approvals.”

Previous directors of CBER would “understand regulatory frameworks and the science of medication creation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that previous people who headed CBER have had.”

This division has an vast portfolio at the agency, Woodcock stated.

“Many people just focuses on the innovative therapies, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those must be looked after,” Woodcock explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a substantial leadership aspect to the position, which oversees more than 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” Woodcock added.

Official Statement and Disputed Initiatives

Regarding questions about Høeg’s fitness for the role and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “questions rely on flawed assumptions”.

“Her resume matches the duties of her job,” the official said, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the agency head's recently launched fast-track approval initiative, a controversial expedited medication authorization process that allegedly worried her preceding directors. “By what process are these medications being selected for this expedited pathway? Who is making the choices?” Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he said, “the agency looks to be trending towards laxer rules of all drugs, with the exception of immunizations.”

Established History on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, track record, some experts have noted. She authored a research paper using unconfirmed public submissions to determine the frequency of heart inflammation following Covid vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership featured revising rules for recently developed shots and discontinuing “unnecessary” vaccines, she stated post-election on a podcast. At the FDA, Høeg has reportedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She’s an complete ideologue who begins with her preconceived notions and tailors the evidence to accommodate the data in a extremely disingenuous, dishonest way,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|